BDNF and depressive symptom measurement: A follow-up study in rats with poststroke depression showed that intranasal administration of BDNF-HA2TAT/AAV increased BDNF mRNA and protein levels in the prefrontal cortex, leading to improvements in neurological function after intranasal gene therapy [130].